Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Oncogene ; 28(46): 4041-52, 2009 Nov 19.
Artigo em Inglês | MEDLINE | ID: mdl-19802002

RESUMO

Neuregulin-1 (NRG1) is both a candidate oncogene and a candidate tumour suppressor gene. It not only encodes the heregulins and other mitogenic ligands for the ERBB family, but also causes apoptosis in NRG1-expressing cells. We found that most breast cancer cell lines had reduced or undetectable expression of NRG1. This included cell lines that had translocation breaks in the gene. Similarly, expression in cancers was generally comparable to or less than that in various normal breast samples. Many non-expressing cell lines had extensive methylation of the CpG island at the principal transcription start site at exon 2 of NRG1. Expression was reactivated by demethylation. Many tumours also showed methylation, whereas normal mammary epithelial fragments had none. Lower NRG1 expression correlated with higher methylation. Small interfering RNA (siRNA)-mediated depletion of NRG1 increased net proliferation in a normal breast cell line and a breast cancer cell line that expressed NRG1. The short arm of chromosome 8 is frequently lost in epithelial cancers, and NRG1 is the most centromeric gene that is always affected. NRG1 may therefore be the major tumour suppressor gene postulated to be on 8p: it is in the correct location, is antiproliferative and is silenced in many breast cancers.


Assuntos
Neoplasias da Mama/genética , Aberrações Cromossômicas , Cromossomos Humanos Par 8 , Metilação de DNA , Inativação Gênica , Genes Supressores de Tumor , Neuregulina-1/genética , Sequência de Bases , Neoplasias da Mama/patologia , Linhagem Celular Tumoral , Proliferação de Células , Mapeamento Cromossômico , Cromossomos Humanos Par 8/química , Cromossomos Humanos Par 8/genética , Ilhas de CpG/genética , Feminino , Regulação Neoplásica da Expressão Gênica , Predisposição Genética para Doença/genética , Humanos , Neuregulina-1/fisiologia , Sítio de Iniciação de Transcrição
2.
Oncogene ; 25(41): 5693-706, 2006 Sep 14.
Artigo em Inglês | MEDLINE | ID: mdl-16636668

RESUMO

The short arm of chromosome 8, 8p, is often rearranged in carcinomas, typically showing distal loss by unbalanced translocation. We analysed 8p rearrangements in 48 breast, pancreatic and colon cancer cell lines by fluorescence in situ hybridization (FISH) and array comparative genomic hybridization, with a tiling path of 0.2 Mb resolution over 8p12 and 1 Mb resolution over chromosome 8. Selected breast lines (MDA-MB-134, MDA-MB-175, MDA-MB-361, T-47D and ZR-75-1) were analysed further. Most cell lines showed loss of 8p distal to a break that was between 31 Mb (5' to NRG1) and the centromere, but the translocations were accompanied by variable amplifications, deletions and inversions proximal to this break. The 8p12 translocation in T-47D was flanked by an inversion of 4 Mb, with a 100 kb deletion at the proximal end. The dicentric t(8;11) in ZR-75-1 carries multiple rearrangements including interstitial deletions, a triplicated translocation junction between NRG1 and a fragment of 11q (unconnected to CCND1), and two separate amplifications, of FGFR1 and CCND1 . We conclude that if there is a tumour suppressor gene on 8p it may be near 31 Mb, for example WRN; but the complexity of 8p rearrangements suggests that they target various genes proximal to 31 Mb including NRG1 and the amplicon centred around ZNF703/FLJ14299.


Assuntos
Neoplasias da Mama/genética , Aberrações Cromossômicas , Cromossomos Humanos Par 8 , Neoplasias do Colo/genética , Neoplasias Pancreáticas/genética , Linhagem Celular Tumoral , Cromossomos Artificiais Bacterianos , Amplificação de Genes , Humanos , Hibridização in Situ Fluorescente , Hibridização de Ácido Nucleico
3.
Biochim Biophys Acta ; 1619(2): 151-8, 2003 Jan 20.
Artigo em Inglês | MEDLINE | ID: mdl-12527111

RESUMO

High resolution magic angle spinning (HRMAS) 1H NMR spectroscopy was used to metabolically characterise Ishikawa cells, a human cell line derived from endometrial adenocarcinoma. The spectra obtained had well-resolved resonances from the nucleotide derivatives of uridine and adenosine. Using a combination of diffusion- and relaxation-weighted spectroscopy, the cellular environment of key metabolites previously identified as related to cell growth was also investigated. As Ishikawa cells are hormone-responsive, the metabolic action of tamoxifen, a selective estrogen receptor modulator (SERM), was also investigated. Cells were exposed to 5, 1 and 0.1 microM tamoxifen. Using the statistical regression technique of prediction to latent structures by partial least squares, a predictive model was built modelling the metabolic profile of the cells against exposure to tamoxifen. These spectral changes were characterised by increased resonance intensities from ethanolamine (3.26 ppm), glucose (3.34-3.94 ppm), glutamate (2.14, 2.32 ppm), tyrosine (7.24 ppm), uridine (7.85 ppm) and adenosine (8.20 ppm), and a relative decrease in contributions from myo-inositol resonances (3.30, 3.62, 3.55 ppm). The nucleotide changes suggest that tamoxifen affects RNA transcription, while the changes in ethanolamine and myo-inositol concentrations are indicative of cell membrane turnover.


Assuntos
Endométrio/metabolismo , Moduladores de Receptor Estrogênico/metabolismo , Espectroscopia de Ressonância Magnética/métodos , Tamoxifeno/metabolismo , Adenocarcinoma , Divisão Celular , Membrana Celular/metabolismo , Relação Dose-Resposta a Droga , Neoplasias do Endométrio , Feminino , Humanos , Valor Preditivo dos Testes , Transcrição Gênica , Células Tumorais Cultivadas
4.
Eur J Cancer ; 36 Suppl 4: S42-3, 2000 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-11056313

RESUMO

Transforming growth factor beta (TGFbeta) immunoreactivity was determined in endometria from non-drug-therapy and tamoxifen-treated patients. Sections were scored for pathology and quantity image analysis performed to determine levels of glandular- or fibrosis-associated TGFbeta1. Tamoxifen-treated patients displayed greater levels of endometrial dysplasia and glandular hyperplasia, in addition to a statistically significant (P<0.0001) elevation in gland-associated TGFbeta1 protein.


Assuntos
Antineoplásicos Hormonais/efeitos adversos , Neoplasias do Endométrio/induzido quimicamente , Tamoxifeno/farmacologia , Fator de Crescimento Transformador beta/metabolismo , Idoso , Neoplasias do Endométrio/metabolismo , Endométrio/efeitos dos fármacos , Endométrio/patologia , Feminino , Humanos , Pessoa de Meia-Idade , Tamoxifeno/efeitos adversos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...